Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Troy’s odyssey

This article was originally published in The Tan Sheet

Executive Summary

Former FDA Chief Counsel Dan Troy and Special Assistant to the Chief Counsel Coleen Klasmeier will join Sidley Austin Brown & Wood this month, the law firm announces Jan. 6. Troy will provide "strategic counsel on FDA-related matters" and practice administrative and constitutional law with a focus on the pharma, biotech and medical device industries; he announced his departure from FDA in November (1"The Tan Sheet" Nov. 22, 2004, p. 10). Klasmeier is joining the firm's life sciences practice with a focus on the pharma, medical device and food industries...

You may also be interested in...



FDA Chief Counsel Warning Letter Review To Continue After Troy’s Departure

The FDA Office of Chief Counsel's review of warning and untitled letters has resulted in the rejection of approximately 5% of letters, outgoing Chief Counsel Daniel Troy said

TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens

The firm licensed the TLR9 agonist SD-101 from Dynavax to test with its pressure-enabled drug delivery technology in liver and pancreatic settings where immuno-oncology has shown moderate efficacy or less.

Advisory Committee For Biogen's Aducanumab Will Test US FDA's 'Substantial Evidence' Flexibility

Given inconsistent study results, robustness of the efficacy evidence is expected to be key focus of the 6 November meeting of the Peripheral and Central Nervous System Drugs Advisory Committee; review could put a December 2019 guidance on the ‘substantial evidence’ standard to the test and offer insight into the amount of flexibility the agency is willing to exercise for neurodegenerative diseases with high unmet need.

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel